Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Nikolina Radulovich, Betty P.K. Poon, Jonathan St-Germain, Jonathan D. Cook, Ivette Valencia-Sama, Benjamin M.M. Grant, Silvia Gabriela Herrera, Jinmin Miao, Brian Raught, Meredith S. Irwin, Jeffrey E. Lee, Jen Jen Yeh, Zhong-Yin Zhang, Ming Sound Tsao, Mitsuhiko Ikura, Michael Ohh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.

Original languageEnglish (US)
Article number224
JournalNature Communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

phosphorylation
Phosphorylation
GTP Phosphohydrolases
Conformations
switches
Switches
cycles
Protein Tyrosine Phosphatases
cancer
Deregulation
effectors
phosphatases
tyrosine
Neoplasms
mutations
Carcinogenesis
Genes
genes
Chemical activation
inhibitors

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., ... Ohh, M. (2019). Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications, 10(1), [224]. https://doi.org/10.1038/s41467-018-08115-8

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. / Kano, Yoshihito; Gebregiworgis, Teklab; Marshall, Christopher B.; Radulovich, Nikolina; Poon, Betty P.K.; St-Germain, Jonathan; Cook, Jonathan D.; Valencia-Sama, Ivette; Grant, Benjamin M.M.; Herrera, Silvia Gabriela; Miao, Jinmin; Raught, Brian; Irwin, Meredith S.; Lee, Jeffrey E.; Yeh, Jen Jen; Zhang, Zhong-Yin; Tsao, Ming Sound; Ikura, Mitsuhiko; Ohh, Michael.

In: Nature Communications, Vol. 10, No. 1, 224, 01.12.2019.

Research output: Contribution to journalArticle

Kano, Y, Gebregiworgis, T, Marshall, CB, Radulovich, N, Poon, BPK, St-Germain, J, Cook, JD, Valencia-Sama, I, Grant, BMM, Herrera, SG, Miao, J, Raught, B, Irwin, MS, Lee, JE, Yeh, JJ, Zhang, Z-Y, Tsao, MS, Ikura, M & Ohh, M 2019, 'Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation', Nature Communications, vol. 10, no. 1, 224. https://doi.org/10.1038/s41467-018-08115-8
Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J et al. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications. 2019 Dec 1;10(1). 224. https://doi.org/10.1038/s41467-018-08115-8
Kano, Yoshihito ; Gebregiworgis, Teklab ; Marshall, Christopher B. ; Radulovich, Nikolina ; Poon, Betty P.K. ; St-Germain, Jonathan ; Cook, Jonathan D. ; Valencia-Sama, Ivette ; Grant, Benjamin M.M. ; Herrera, Silvia Gabriela ; Miao, Jinmin ; Raught, Brian ; Irwin, Meredith S. ; Lee, Jeffrey E. ; Yeh, Jen Jen ; Zhang, Zhong-Yin ; Tsao, Ming Sound ; Ikura, Mitsuhiko ; Ohh, Michael. / Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. In: Nature Communications. 2019 ; Vol. 10, No. 1.
@article{f4c272cc431d4d72b43e00039bd350a0,
title = "Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation",
abstract = "Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.",
author = "Yoshihito Kano and Teklab Gebregiworgis and Marshall, {Christopher B.} and Nikolina Radulovich and Poon, {Betty P.K.} and Jonathan St-Germain and Cook, {Jonathan D.} and Ivette Valencia-Sama and Grant, {Benjamin M.M.} and Herrera, {Silvia Gabriela} and Jinmin Miao and Brian Raught and Irwin, {Meredith S.} and Lee, {Jeffrey E.} and Yeh, {Jen Jen} and Zhong-Yin Zhang and Tsao, {Ming Sound} and Mitsuhiko Ikura and Michael Ohh",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-018-08115-8",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

AU - Kano, Yoshihito

AU - Gebregiworgis, Teklab

AU - Marshall, Christopher B.

AU - Radulovich, Nikolina

AU - Poon, Betty P.K.

AU - St-Germain, Jonathan

AU - Cook, Jonathan D.

AU - Valencia-Sama, Ivette

AU - Grant, Benjamin M.M.

AU - Herrera, Silvia Gabriela

AU - Miao, Jinmin

AU - Raught, Brian

AU - Irwin, Meredith S.

AU - Lee, Jeffrey E.

AU - Yeh, Jen Jen

AU - Zhang, Zhong-Yin

AU - Tsao, Ming Sound

AU - Ikura, Mitsuhiko

AU - Ohh, Michael

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.

AB - Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled ‘dark state’.

UR - http://www.scopus.com/inward/record.url?scp=85060053894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060053894&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-08115-8

DO - 10.1038/s41467-018-08115-8

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 224

ER -